The obesity drug boom is just getting started: podcast

By
A injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo

A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing Rights

LONDON, Sept 5 (Reuters Breakingviews) - Over 1 bln people are obese, the WHO reckons. Denmark’s Novo Nordisk is ahead of the pharma pack with its Wegovy weight-loss drug. In this Exchange podcast, recorded in August as a Reuters Newsmaker, CEO Lars Jorgensen says the market will be big enough for other players too.

Listen to the podcast

Follow @aimeedonnellan on X

(The host is a Reuters Breakingviews columnist. The opinions expressed are her own.)

Subscribe to Breakingviews’ podcasts, Viewsroom and The Exchange.

Editing by Oliver Taslic

Our Standards: The Thomson Reuters Trust Principles.

Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Acquire Licensing Rights, opens new tab

Read Next